SP 11.06 Patients with Inflammatory Bowel Disease Undergoing Surgical Resection Following Biological Therapy are at Higher Risk of Having Surgical Site Infections - A Meta-Analysis
Mukhil Rajendran, Mohamed Yasser, Muhammed S Sajid, Mirza K Baig, Alferado TonsiAbstract
Aim
The objective of this study is to do a meta-analysis and check the influence of biological therapy treatment in patients undergoing surgery for inflammatory bowel disease (IBD).
Methods
A meta-analysis was performed in accordance with the PRISMA guidelines. A comprehensive literature search was conducted across Google Scholar, PubMed, Ovid MEDLINE, Embase, CINAHL and Emcare to identify relevant comparative studies. Statistical analysis was performed using RevMan software version 5.5. Outcomes were pooled using a random-effects model.
Results
Six comparative studies comprising 1,775 patients were included, of whom 785 received preoperative biological therapy and 990 did not. No significant differences were observed between the biologics and no biologics groups in post-operative length of hospital stay [Mean Difference −0.18, 95% CI (−0.88, 0.53), P=0.62], anastomotic leak [Odds Ratio 0.84, 95% CI (0.34, 2.04), P=0.69], wound dehiscence [Odds Ratio 1.13, 95% CI (0.13, 9.94), P=0.91], thrombotic events [Odds Ratio 0.70, 95% CI (0.33, 1.49), P=0.36], or bowel obstruction [Odds Ratio 0.56, 95% CI (0.16, 1.92), P=0.35]. In contrast, the incidence of surgical site infections (SSIs), including pelvic abscesses, was significantly higher in patients who received biologics preoperatively [Odds Ratio 1.40, 95% CI (1.02, 1.93), P=0.04].
Conclusion
The preoperative biological therapy in patients undergoing surgery for IBD is associated with higher SSI rate.